Puducherry capacity enhancement underway to meet enhanced market demand
Currently WHO-GMP approved, PICs/EMEA compliant, audit expected post EU filing in 2025
M/s Biogenomics Limited is coming up with a state of art biopharmaceutical manufacturing facility to produce Human Insulin and its analog products, at Sanand GIDC II, Ahmedabad.
The facility shall comprise of Drug Substance manufacturing unit, Drug Product manufacturing unit, with dedicated warehouse and supporting utilities and future expansion space for Admin building, Drug Substance, Drug Product and Warehouse expansion.
The new facility will be designed and implemented for supplying products to India, EU, US and across the global market.
The process operations and equipment shall be designed in accordance with guidelines of WHO, PIC/s, EMA, US FDA and Schedule M.
DS Manufacturing suite at 5000 L Fermenter (Working Volume) scale with Production capacity of 330 Kg DS at Phase 1 and add on 120 KG at Phase 2.
Drug Product Facility shall be equipped with Primary packaging machines, secondary and tertiary packaging machines with capacity of producing 20Million cartridges and 6 Million Vials per annum.
New fill + finish plant in Oman with capacity of 20 million cartridges is being constructed.
This plant will supply to MENA region and other developed markets
©2021, All rights reserved, BioGenomics Limited.
Designed & Developed by W